Carl J. Arbes

Array ( [id] => 20385403 [patent_doc_number] => 12485112 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-02 [patent_title] => Pharmaceutical composition [patent_app_type] => utility [patent_app_number] => 18/407337 [patent_app_country] => US [patent_app_date] => 2024-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2723 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18407337 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20171708 [patent_doc_number] => 12390428 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-08-19 [patent_title] => Bupropion and dextromethorphan for reduction of suicide risk in depression patients [patent_app_type] => utility [patent_app_number] => 18/397220 [patent_app_country] => US [patent_app_date] => 2023-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 0 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 116 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18397220 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20114990 [patent_doc_number] => 12364674 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-22 [patent_title] => Compounds and combinations thereof for treating neurological and psychiatric conditions [patent_app_type] => utility [patent_app_number] => 18/541574 [patent_app_country] => US [patent_app_date] => 2023-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 925 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18541574 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19447381 [patent_doc_number] => 20240307511 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-19 [patent_title] => AAV9-MEDIATED GENE THERAPY FOR TREATING MUCOPOLYSACCHARIDOSIS TYPE I [patent_app_type] => utility [patent_app_number] => 18/538866 [patent_app_country] => US [patent_app_date] => 2023-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54255 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 151 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18538866 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19593104 [patent_doc_number] => 12150922 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-11-26 [patent_title] => Methods of inhibiting cyclooxygenase (COX) using tolterodine [patent_app_type] => utility [patent_app_number] => 18/533619 [patent_app_country] => US [patent_app_date] => 2023-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4843 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18533619 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19599459 [patent_doc_number] => 20240390339 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-28 [patent_title] => USE OF A PHOSPHODIESTERASE 10 INHIBITOR FOR THE TREATMENT OF TOURETTE SYNDROME [patent_app_type] => utility [patent_app_number] => 18/529506 [patent_app_country] => US [patent_app_date] => 2023-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10426 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18529506 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19065607 [patent_doc_number] => 20240100033 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => Anti-Androgens For The Treatment Of Non-Metastatic Castration-Resistant Prostate Cancer [patent_app_type] => utility [patent_app_number] => 18/517512 [patent_app_country] => US [patent_app_date] => 2023-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20144 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18517512 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19065634 [patent_doc_number] => 20240100060 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM [patent_app_type] => utility [patent_app_number] => 18/510986 [patent_app_country] => US [patent_app_date] => 2023-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24908 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18510986 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19930310 [patent_doc_number] => 12303503 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2025-05-20 [patent_title] => Use of dextromethorphan in combination with CYP2D6 and CYP3A4 enzyme inhibitors for the treatment of pain [patent_app_type] => utility [patent_app_number] => 18/510882 [patent_app_country] => US [patent_app_date] => 2023-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5078 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 163 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18510882 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19065576 [patent_doc_number] => 20240100002 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => Compositions and Methods for Treating Chronic Inflammation and Inflammatory Diseases [patent_app_type] => utility [patent_app_number] => 18/509114 [patent_app_country] => US [patent_app_date] => 2023-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37252 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18509114 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19049270 [patent_doc_number] => 20240091239 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-21 [patent_title] => ADMINISTRATION OF TESTOSTERONE COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 18/502166 [patent_app_country] => US [patent_app_date] => 2023-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22888 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18502166 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19425293 [patent_doc_number] => 12084696 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-10 [patent_title] => Compositions and methods for using engineered deubiquitinases for probing ubiquitin-dependent cellular processes [patent_app_type] => utility [patent_app_number] => 18/501966 [patent_app_country] => US [patent_app_date] => 2023-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 24 [patent_no_of_words] => 10014 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18501966 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19441453 [patent_doc_number] => 12091695 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-17 [patent_title] => Compositions and methods for using engineered deubiquitinases for probing ubiquitin-dependent cellular processes [patent_app_type] => utility [patent_app_number] => 18/501967 [patent_app_country] => US [patent_app_date] => 2023-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 24 [patent_no_of_words] => 10013 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18501967 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19462319 [patent_doc_number] => 20240315988 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-26 [patent_title] => EUTECTIC FORMULATIONS OF CYCLOBENZAPRINE HYDROCHLORIDE AND AMITRIPTYLINE HYDROCHLORIDE [patent_app_type] => utility [patent_app_number] => 18/385468 [patent_app_country] => US [patent_app_date] => 2023-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18149 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18385468 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19332550 [patent_doc_number] => 20240246980 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-25 [patent_title] => MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR D AND RELATED PRODUCTS AND METHODS [patent_app_type] => utility [patent_app_number] => 18/496540 [patent_app_country] => US [patent_app_date] => 2023-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40144 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18496540 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19332505 [patent_doc_number] => 20240246935 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-25 [patent_title] => ARYL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT MODULATE IKZF2 [patent_app_type] => utility [patent_app_number] => 18/496709 [patent_app_country] => US [patent_app_date] => 2023-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30762 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18496709 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18986338 [patent_doc_number] => 20240058307 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-22 [patent_title] => CHLORINATED TETRALIN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 18/490993 [patent_app_country] => US [patent_app_date] => 2023-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13796 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18490993 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18986385 [patent_doc_number] => 20240058354 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-22 [patent_title] => PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM [patent_app_type] => utility [patent_app_number] => 18/489685 [patent_app_country] => US [patent_app_date] => 2023-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23822 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18489685 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18972326 [patent_doc_number] => 20240052418 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-15 [patent_title] => METHOD FOR PREDICTING A SUBJECT'S RESPONSE TO SLC MODULATOR THERAPY [patent_app_type] => utility [patent_app_number] => 18/483952 [patent_app_country] => US [patent_app_date] => 2023-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38539 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -93 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18483952 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18953509 [patent_doc_number] => 20240041836 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-08 [patent_title] => PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE ACTING AS A FUNCTIONAL ANTAGONIST FOR S1PR1 AND S1PR4 [patent_app_type] => utility [patent_app_number] => 18/477175 [patent_app_country] => US [patent_app_date] => 2023-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6993 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18477175 [rel_patent_id] =>[rel_patent_doc_number] =>)